logo-loader
HealthPharma & Biotech
Avacta Group PLC

Avacta Group trading in line in "year of very significant progress"

An update on the collaboration with Moderna is planned for the first half of this year

Avacta technology
Half year revenue, operating losses and cash balances were in line with market forecasts

Avacta Group PLC (LON:AVCT) traded in line with market forecasts in the first half of its fiscal year.

The developer of Affimer biotherapeutics and reagents, released a statement ahead of its annual general meeting, highlighting a number of developments in 2018 that validated its technology and business model.

WATCH: Avacta's Alastair Smith encouraged by significant progress and share price momentum

Chief executive officer, Dr Alastair Smith, said 2018 had been a period of “very strong progress”.

Among the highlights of the year were the partnership with LG Chem, which sent the company’s shares soaring in December, and the research collaboration with leading scientists at Tufts University Medical School.

The company also announced a licensing deal last year with New England Biolabs and appointed Jose Saro as the chief medical officer.

“As we move our first programmes into the clinic we are all looking forward to working with Jose to validate the Affimer platform in-human and build an exciting pipeline of valuable therapeutic assets,” Dr Smith said.

The company said it is continuing to build the in-vivo (i.e. in living cells) pharmacology data packages for its lead immune checkpoint programmes, the PDL1 and LAG3 antagonists. The company is aiming to initiate first-in-human clinical studies for the Affimer drug platform in 2020.

“I look forward to updating the market on progress during 2019 which I expect to be a year of very significant progress for the company," Smith added.

House broker finnCap said the updates relating to its TMAC Affimer drug conjugate platform and its collaboration with Moderna are encouraging, and provide further evidence of the incremental value being created in the Affimer-driven technology platforms.

“Management is confident that there will be multiple reagent licensing deals in 2019, given the pipeline of late-stage interest from potential parties. Equally, we would hope/expect further therapeutic licences during 2019, given the preclinical progress that is being made, and building on the LG Chem development deal in December, which has a bio-dollar value of up to US$300mln plus royalties,” the broker said, as it reiterated its target price of 120p.

Avacta shares were up 1.1p at 38.5p in lunchtime trading.

Quick facts: Avacta Group PLC

Price: £0.21

Market: AIM
Market Cap: £24.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read